Cargando…

Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency

The diagnostic evaluation and clinical characterization of rare hereditary anemia (RHA) is to date still challenging. In particular, there is little knowledge of the broad metabolic impact of many of the molecular defects underlying RHA. In this study we explored the potential of untargeted metabolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dooijeweert, Birgit, Broeks, Melissa H., Verhoeven-Duif, Nanda M., van Beers, Eduard J., Nieuwenhuis, Edward E.S., van Solinge, Wouter W., Bartels, Marije, Jans, Judith J.M., van Wijk, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485668/ https://www.ncbi.nlm.nih.gov/pubmed/33054133 http://dx.doi.org/10.3324/haematol.2020.266957

Ejemplares similares

Dried blood spot metabolomics reveals a metabolic fingerprint with diagnostic potential for Diamond Blackfan Anaemia
por: van Dooijeweert, Birgit, et al.
Publicado: (2021)

Metabolic Fingerprint in Hereditary Spherocytosis Correlates With Red Blood Cell Characteristics and Clinical Severity
por: van Dooijeweert, Birgit, et al.
Publicado: (2021)

GATA-1 Defects in Diamond–Blackfan Anemia: Phenotypic Characterization Points to a Specific Subset of Disease
por: van Dooijeweert, Birgit, et al.
Publicado: (2022)

PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT
por: van der Veen, Sigrid, et al.
Publicado: (2023)

Transfusion burden in early childhood plays an important role in iron overload in Diamond‐Blackfan anaemia
por: de Wilde, Jonathan R. A., et al.
Publicado: (2022)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
por: Grootendorst, Simon, et al.
Publicado: (2021)

Untargeted metabolic analysis in dried blood spots reveals metabolic signature in 22q11.2 deletion syndrome
por: Korteling, Dorinde, et al.
Publicado: (2022)

Untargeted Metabolomics for Metabolic Diagnostic Screening with Automated Data Interpretation Using a Knowledge-Based Algorithm
por: Haijes, Hanneke A., et al.
Publicado: (2020)

A Proposed Concept for Defective Mitophagy Leading to Late Stage Ineffective Erythropoiesis in Pyruvate Kinase Deficiency
por: van Vuren, Annelies Johanna, et al.
Publicado: (2021)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: M., VAN DIJK, et al.
Publicado: (2022)

Inborn disorders of the malate aspartate shuttle
por: Broeks, Melissa H., et al.
Publicado: (2021)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

A Comprehensive Analysis of the Erythropoietin-erythroferrone-hepcidin Pathway in Hereditary Hemolytic Anemias
por: van Vuren, Annelies J., et al.
Publicado: (2021)

P717: AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES
por: de Wilde, Jonathan, et al.
Publicado: (2023)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: van der Veen, S., et al.
Publicado: (2022)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: S., VAN DER VEEN, et al.
Publicado: (2022)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

The variable manifestations of disease in pyruvate kinase deficiency and their management
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Direct Infusion Based Metabolomics Identifies Metabolic Disease in Patients’ Dried Blood Spots and Plasma
por: Haijes, Hanneke A., et al.
Publicado: (2019)

A one-year pilot study comparing direct-infusion high resolution mass spectrometry based untargeted metabolomics to targeted diagnostic screening for inherited metabolic diseases
por: Willems, Anke P., et al.
Publicado: (2023)

The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients: Genotype-Phenotype Correlation in Hereditary Spherocytosis
por: van Vuren, Annelies, et al.
Publicado: (2019)

P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: Rab, M., et al.
Publicado: (2022)

PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: M., RAB, et al.
Publicado: (2022)

Megakaryocyte lineage development is controlled by modulation of protein acetylation
por: Bartels, Marije, et al.
Publicado: (2018)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

Inborn errors of enzymes in glutamate metabolism
por: Rumping, Lynne, et al.
Publicado: (2019)

Red blood cell vesiculation in hereditary hemolytic anemia
por: Alaarg, Amr, et al.
Publicado: (2013)

Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial
por: van Vuren, Annelies, et al.
Publicado: (2022)

Fingerprinting Acute Digestive Diseases by Untargeted NMR Based Metabolomics
por: Takis, Panteleimon G., et al.
Publicado: (2018)

Accurate discrimination of Hartnup disorder from other aminoacidurias using a diagnostic ratio
por: Haijes, H.A., et al.
Publicado: (2019)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

Understanding acute metabolic decompensation in propionic and methylmalonic acidemias: a deep metabolic phenotyping approach
por: Haijes, H. A., et al.
Publicado: (2020)

Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics
por: Haijes, Hanneke A., et al.
Publicado: (2019)

Vitamin B6 in Plasma and Cerebrospinal Fluid of Children
por: Albersen, Monique, et al.
Publicado: (2015)

Squeezing for Life – Properties of Red Blood Cell Deformability
por: Huisjes, Rick, et al.
Publicado: (2018)

Comparison of dried blood spot and plasma sampling for untargeted metabolomics
por: Tobin, Nicole H., et al.
Publicado: (2021)

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease From Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling
por: van Vuren, Annelies J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n32bfq8f72m4870ae9dgsa2uv0